amphastar.com (AMPH): Price to Earnings Adjusted for Growth Rate

Vertical integration of complex inhaler production has allowed Amphastar Pharmaceuticals (AMPH) management to optimize costs, which is confirmed by the PEG ratio with the current metric value at 2.71. This chart highlights a strategy of capturing a niche in hard-to-replicate injectables. High technological barriers and FDA approval reliably protect profits from cheap generics, ensuring sustainable business growth.

This indicator compares the current market P/E multiple with the net income expansion rate, identifying undervalued assets with high growth potential when the value is below one. The PEG ratio analysis for Amphastar Pharmaceuticals (AMPH) confirms the business's resilience during its transition from a narrow focus on generics to the implementation of its own proprietary drug delivery systems.